Rebekka Schäfer1, Vratislav Strnad2, Csaba Polgár3, Wolfgang Uter4, Guido Hildebrandt5, Oliver J Ott2, Daniela Kauer-Dorner6, Hellen Knauerhase7, Tibor Major8, Jaroslaw Lyczek9, Jose Luis Guinot10, Jürgen Dunst11, Cristina Gutierrez Miguelez12, Pavel Slampa13, Michael Allgäuer14, Kristina Lössl15, György Kovács16, Arnt-René Fischedick17, Rainer Fietkau18, Alexandra Resch6, Anna Kulik19, Leo Arribas10, Peter Niehoff20, Ferran Guedea12, Annika Schlamann21, Christine Gall4, Bülent Polat22. 1. Department of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany. Electronic address: schaefer_r2@ukw.de. 2. Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany. 3. Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary; Department of Oncology, Semmelweis University, Budapest, Hungary. 4. Department of Medical Informatics, Biometry and Epidemiology, University Erlangen-Nuremberg, Erlangen, Germany. 5. Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany; Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany. 6. Department of Radiation Oncology, University Hospital AKH Wien, Vienna, Austria. 7. Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany. 8. Center of Radiotherapy, National Institute of Oncology, Budapest, Hungary. 9. Podkarpacki Hospital Cancer Center Brzozow, Brzozow, Poland; Brachytherapy Department, Centrum Onkologii-Instytut im Marii Skłodowskiej, Warsaw, Poland. 10. Department of Radiation Oncology, Valencian Institute of Oncology, Valencia, Spain. 11. Department of Radiation Oncology, University Hospital Kiel, Kiel, Germany. 12. Department of Radiation Oncology, Catalan Institute of Oncology, Barcelona, Spain. 13. Department of Radiation Oncology, Masaryk Memorial Cancer Institute and Faculty of Medicine, Brno, Czech Republic. 14. Department of Radiation Oncology, Hospital Barmherzige Brüder, Regensburg, Germany. 15. Department of Radiation Oncology, University Hospital Bern, Inselspital, Switzerland. 16. Interdisciplinary Brachytherapy Unit, University of Lubeck/Universitätsklinikum Schleswig-Holstein Campus Lubeck, Lubeck, Germany. 17. Department of Radiation Oncology, Clemens Hospital, Münster, Germany. 18. Department of Radiation Oncology, University Hospital Erlangen, Erlangen, Germany; Department of Radiation Oncology, University Hospital Rostock, Rostock, Germany. 19. Brachytherapy Department, Centrum Onkologii-Instytut im Marii Skłodowskiej, Warsaw, Poland. 20. Department of Radiation Oncology, University Hospital Kiel, Kiel, Germany; Department of Radiotherapy, Sana Hospital Offenbach, Offenbach, Germany. 21. Department of Radiation Oncology, University Hospital Leipzig, Leipzig, Germany. 22. Department of Radiation Oncology, University Hospital Würzburg, Würzburg, Germany.
Abstract
BACKGROUND: Previous results from the GEC-ESTRO trial showed that accelerated partial breast irradiation (APBI) using multicatheter brachytherapy in the treatment of early breast cancer after breast-conserving surgery was non-inferior to whole-breast irradiation in terms of local control and overall survival. Here, we present 5-year results of patient-reported quality of life. METHODS: We did this randomised controlled phase 3 trial at 16 hospitals and medical centres in seven European countries. Patients aged 40 years or older with 0-IIA breast cancer were randomly assigned (1:1) after breast-conserving surgery (resection margins ≥2 mm) to receive either whole-breast irradiation of 50 Gy with a boost of 10 Gy or APBI using multicatheter brachytherapy. Randomisation was stratified by study centre, tumour type, and menopausal status, with a block size of ten and an automated dynamic algorithm. There was no masking of patients or investigators. The primary endpoint of the trial was ipsilateral local recurrence. Here, we present 5-year results of quality of life (a prespecified secondary endpoint). Quality-of-life questionnaires (European Organisation for Research and Treatment of Cancer QLQ-C30, breast cancer module QLQ-BR23) were completed before radiotherapy (baseline 1), immediately after radiotherapy (baseline 2), and during follow-up. We analysed the data according to treatment received (as-treated population). Recruitment was completed in 2009, and long-term follow-up is continuing. The trial is registered at ClinicalTrials.gov, number NCT00402519. FINDINGS:Between April 20, 2004, and July 30, 2009, 633 patients had accelerated partial breast irradiation and 551 patients had whole-breast irradiation. Quality-of-life questionnaires at baseline 1 were available for 334 (53%) of 663 patients in the APBI group and 314 (57%) of 551 patients in the whole-breast irradiation group; the response rate was similar during follow-up. Global health status (range 0-100) was stable in both groups: at baseline 1, APBI group mean score 65·5 (SD 20·6) versus whole-breast irradiation group 64·6 (19·6), p=0·37; at 5 years, APBI group 66·2 (22·2) versus whole-breast irradiation group 66·0 (21·8), p=0·94. The only moderate, significant difference (difference of 10-20 points) between the groups was found in the breast symptoms scale. Breast symptom scores were significantly higher (ie, worse) after whole-breast irradiation than after APBI at baseline 2 (difference of means 13·6, 95% CI 9·7-17·5; p<0·0001) and at 3-month follow-up (difference of means 12·7, 95% CI 9·8-15·6; p<0·0001). INTERPRETATION:APBI with multicatheter brachytherapy was not associated with worse quality of life compared with whole-breast irradiation. This finding supports APBI as an alternative treatment option after breast-conserving surgery for patients with early breast cancer. FUNDING: German Cancer Aid.
RCT Entities:
BACKGROUND: Previous results from the GEC-ESTRO trial showed that accelerated partial breast irradiation (APBI) using multicatheter brachytherapy in the treatment of early breast cancer after breast-conserving surgery was non-inferior to whole-breast irradiation in terms of local control and overall survival. Here, we present 5-year results of patient-reported quality of life. METHODS: We did this randomised controlled phase 3 trial at 16 hospitals and medical centres in seven European countries. Patients aged 40 years or older with 0-IIA breast cancer were randomly assigned (1:1) after breast-conserving surgery (resection margins ≥2 mm) to receive either whole-breast irradiation of 50 Gy with a boost of 10 Gy or APBI using multicatheter brachytherapy. Randomisation was stratified by study centre, tumour type, and menopausal status, with a block size of ten and an automated dynamic algorithm. There was no masking of patients or investigators. The primary endpoint of the trial was ipsilateral local recurrence. Here, we present 5-year results of quality of life (a prespecified secondary endpoint). Quality-of-life questionnaires (European Organisation for Research and Treatment of Cancer QLQ-C30, breast cancer module QLQ-BR23) were completed before radiotherapy (baseline 1), immediately after radiotherapy (baseline 2), and during follow-up. We analysed the data according to treatment received (as-treated population). Recruitment was completed in 2009, and long-term follow-up is continuing. The trial is registered at ClinicalTrials.gov, number NCT00402519. FINDINGS: Between April 20, 2004, and July 30, 2009, 633 patients had accelerated partial breast irradiation and 551 patients had whole-breast irradiation. Quality-of-life questionnaires at baseline 1 were available for 334 (53%) of 663 patients in the APBI group and 314 (57%) of 551 patients in the whole-breast irradiation group; the response rate was similar during follow-up. Global health status (range 0-100) was stable in both groups: at baseline 1, APBI group mean score 65·5 (SD 20·6) versus whole-breast irradiation group 64·6 (19·6), p=0·37; at 5 years, APBI group 66·2 (22·2) versus whole-breast irradiation group 66·0 (21·8), p=0·94. The only moderate, significant difference (difference of 10-20 points) between the groups was found in the breast symptoms scale. Breast symptom scores were significantly higher (ie, worse) after whole-breast irradiation than after APBI at baseline 2 (difference of means 13·6, 95% CI 9·7-17·5; p<0·0001) and at 3-month follow-up (difference of means 12·7, 95% CI 9·8-15·6; p<0·0001). INTERPRETATION:APBI with multicatheter brachytherapy was not associated with worse quality of life compared with whole-breast irradiation. This finding supports APBIas an alternative treatment option after breast-conserving surgery for patients with early breast cancer. FUNDING: German Cancer Aid.
Authors: Matthew N Mills; Nicholas W Russo; Matthew Fahey; Ronica H Nanda; Sunny Raiker; Jessica Jastrzebski; Lisa L Stout; Jason P Wilson; Taghrid A Altoos; Kathleen G Allen; Peter W Blumencranz; Roberto Diaz Journal: Oncologist Date: 2021-10-04
Authors: Csaba Polgár; Zsuzsanna Kahán; Olivera Ivanov; Martin Chorváth; Andrea Ligačová; András Csejtei; Gabriella Gábor; László Landherr; László Mangel; Árpád Mayer; János Fodor Journal: Pathol Oncol Res Date: 2022-06-23 Impact factor: 2.874
Authors: Sara Garduño-Sánchez; Isabel Villanego-Beltrán; María Dolores de Las Peñas-Cabrera; Javier Jaén-Olasolo Journal: Clin Transl Oncol Date: 2022-03-30 Impact factor: 3.340
Authors: Courtney M Lattimore; Max O Meneveau; Gina R Petroni; Nikole E Varhegyi; Gabriella C Squeo; Timothy N Showalter; Shayna L Showalter Journal: Brachytherapy Date: 2022-02-02 Impact factor: 2.441
Authors: Nieves G Rodriguez-Ibarria; Ma Beatriz Pinar; Laura García; M Auxiliadora Cabezón; Marta Lloret; Ma Dolores Rey-Baltar; J Ignacio Rdguez-Melcón; Pedro C Lara Journal: Breast Date: 2020-04-22 Impact factor: 4.380